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Impact of Haemophilus influenzae type b
conjugate vaccine on bacterial meningitis 
in the Dominican Republic
Ellen H. Lee,1,2 Miriam Corcino,3 Arelis Moore,3 Zacarias Garib,3
Chabela Peña,4 Jacqueline Sánchez,4 Josefina Fernández,4
Jesús M. Feris-Iglesias,4 and Brendan Flannery1
Objectives. Widespread use of Haemophilus influenzae type b (Hib) vaccines has dra-
matically reduced the burden of Hib disease throughout the Americas. Few studies have eval-
uated the impact of Hib vaccination on non-culture-confirmed disease. This study analyzed
trends in probable bacterial meningitis before and after the introduction of Hib vaccine in the
Dominican Republic and estimated vaccine effectiveness against Hib meningitis. 
Methods. Meningitis cases among children < 5 years of age were identified from admission
records of the main pediatric hospital in Santo Domingo during 1998–2004. Laboratory crite-
ria were used to classify meningitis cases with probable bacterial etiology; confirmed cases had
positive bacterial culture or antigen detection in cerebrospinal fluid. Cumulative incidence
rates of confirmed and probable bacterial meningitis were calculated for children living in the
National District. Confirmed cases of Hib meningitis were enrolled in a case-control study
with age- and neighborhood-matched control children to calculate vaccine effectiveness. 
Results. Before vaccine introduction, annual rates of meningitis with probable bacterial eti-
ology were 49 cases per 100 000 children < 5 years old; Hib accounted for 60% of confirmed
bacterial cases. During 2002–2004, after vaccine introduction, annual rates of probable bacte-
rial meningitis were 65% lower at 16 cases per 100 000, and Hib accounted for 26% of con-
firmed cases. Rates of Hib meningitis and probable bacterial meningitis with no determined
etiology declined by 13 and 17 cases per 100 000, respectively. 
Conclusions. Introduction of Hib vaccine substantially reduced the incidence of confirmed
and probable bacterial meningitis in the Dominican Republic. The estimated impact of Hib
vaccination was twice as great when non-culture-confirmed disease was included. 
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Haemophilus influenzae type b (Hib)
conjugate vaccines are included in rou-
tine childhood immunizations in all
countries in Latin America and the
Caribbean except Haiti (1). Hib was a
leading bacterial cause of meningitis in
Latin American children before the in-
troduction of conjugate vaccines (2, 3),
which led to dramatic reductions in
the number of cases of Hib meningitis
(4–6). However, confirmed cases of
Hib meningitis represent only a frac-
tion of all Hib disease. Analysis of lab-
oratory data from hospitals in Argen-
tina, South Africa, and Rwanda
showed significant reductions in sus-
pected bacterial meningitis cases of un-
determined etiology after Hib vaccine
was introduced in these countries, sug-
gesting the potential to use surrogate
markers of bacterial meningitis to mea-
sure the impact of Hib vaccine (7, 8).
Difficulties in isolating Hib often re-
sult in underappreciation of the dis-
ease burden and potential benefits of
vaccination. In developing countries
like the Dominican Republic, the intro-
duction of Hib vaccine was delayed
because of the relatively high cost 
of conjugate vaccines and the lack of 
data on disease burden. Demonstration
of the impact of the introduction of
Hib vaccine on reductions in disease
burden is important for the sustaina-
bility of the vaccination program. Eval-
uations of vaccine impact and cost-
effectiveness analyses should include
effects on non-culture-confirmed dis-
ease endpoints to provide a truer pic-
ture of vaccine benefits (9).
The objective of this study was to
evaluate the impact of routine child-
hood immunization against Hib on
both confirmed and probable cases of
bacterial meningitis in the Dominican
Republic, where bacterial meningitis
has been a reportable disease since
1998 (10). Before the introduction of
Hib conjugate vaccines into the routine
infant immunization schedule in 2001,
Hib was the leading cause of bacterial
meningitis in children after the first
month of life (11). This report summa-
rizes trends in confirmed and probable
cases of bacterial meningitis among
children admitted to the main pedi-
atric referral hospital in Santo Do-
mingo from 1998 through 2004 and
presents the results of a case-control
study of the effectiveness of Hib vac-
cine against culture-confirmed disease.
MATERIALS AND METHODS
Study population
The Dominican Republic is a devel-
oping country in the Caribbean region
with a population of 9.6 million. Its
child mortality rate of 35 deaths per 
1 000 live births ranks second highest
behind Haiti among Caribbean na-
tions and ninth among the 35 countries
in the Americas region (12, 13). The
Dominican Republic, with a per capita
gross national income of more than 
US $2 000, is not among the 72 poor-
est countries eligible to receive sup-
port for immunizations through the
Global Alliance for Vaccines and Im-
munization (14). The national govern-
ment funds approximately 60% of rou-
tine immunizations in the Dominican
Republic (12), with the balance pro-
vided by international donors. From
2001 through 2005, Hib conjugate vac-
cine for routine childhood immuni-
zation was provided by a grant from
the Japan International Cooperation
Agency (15).
In July and August 2001, before Hib
conjugate vaccine was introduced in-
to the routine immunization schedule,
a national campaign was conducted 
to vaccinate all children 2 to 35
months of age with a single dose of
Hib conjugate vaccine (PRP-CRM197,
mutant diphtheria toxin conjugate,
HibTITER™, Lederle Praxis, Pearl
River, United States of America). Vac-
cination data suggested that about
76% of the target population was vac-
cinated. Beginning in December 2001,
Hib conjugate vaccine (PRP-T, tetanus
toxoid conjugate, Hiberix™, Glaxo
SmithKline, Rixensart, Belgium) was
introduced into the routine immuniza-
tion schedule as part of a pentavalent
combination with diphtheria, whole
cell pertussis, tetanus, and hepatitis B
vaccines (Tritanrix®, GlaxoSmithKline),
with doses recommended at 2, 4, and 
6 months of age. According to official
estimates, national coverage with
three doses of Hib vaccine ranged
from 75% to 83% during 2002–2004;
World Health Organization–United
Nations Children’s Fund (WHO-
UNICEF) estimates for the same pe-
riod ranged from 65% to 83% (12).
Surveillance for bacterial meningitis
The National District—including
the capital, Santo Domingo, and the
surrounding periurban area—accounts
for approximately 40% of the coun-
try’s population, with 300 000 children
less than 5 years of age. In 1998 and
1999, active, population-based surveil-
lance for bacterial meningitis in eight
hospitals (four public and four pri-
vate) in the National District docu-
mented an incidence of 13 cases of Hib
meningitis per 100 000 children less
than 5 years of age (11). During this 
2-year period, surveillance officers
regularly reviewed laboratory records
and admission logs to identify case pa-
tients and completed standardized
case report forms. From 2000 through
2004, surveillance for pediatric menin-
gitis cases was passive.
During the active surveillance pe-
riod, Clínica Infantil Dr. Robert Reid
Cabral (CIRRC), the main pediatric re-
ferral hospital in the country, ac-
counted for approximately 80% of all
confirmed and probable cases of bacte-
rial meningitis identified. Between
1998 and 2004, clinical criteria for hos-
pitalizing children with suspected
meningitis and for performing lumbar
puncture, as well as routine laboratory
testing for etiologic agents, did not
change at CIRRC. In 2004, we retro-
spectively reviewed all admissions
and laboratory records for children
hospitalized at CIRRC with bacterial
meningitis.
Case definitions
Probable bacterial meningitis was
defined as a child hospitalized with
suspected meningitis from whom the
cerebrospinal fluid (CSF) was either
visibly turbid or met two of the fol-
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lowing criteria: glucose < 40 mg/dL,
protein > 45 mg/dL, ≥ 100 leukocytes/
mm3, or > 80% polymorphonuclear
cells. Confirmed bacterial meningitis
was defined as a child hospitalized
with suspected meningitis with posi-
tive bacterial culture or antigen detec-
tion by latex agglutination in CSF. 
H. influenzae isolates were serotyped
by latex agglutination. For trend
analyses, probable case counts include
all confirmed cases that met criteria 
for probable bacterial meningitis. Case
patients residing outside the National
District at the time of illness were
excluded.
Case-control study
We conducted a retrospective case-
control study in October 2004 to inves-
tigate undervaccination as a factor
contributing to ongoing transmission
of Hib after introduction of the conju-
gate vaccine. Children hospitalized
during the study period (26 August
2001 to 26 October 2004) with con-
firmed Hib meningitis were enrolled
as cases. Case patients had to be at
least 60 days old and reside in the Na-
tional District at the time of illness.
Cases occurring within 2 weeks of the
national Hib vaccination campaign in
July and August 2001 were excluded.
Hib vaccine doses were considered
valid if administered at least 15 days
before illness. For both cases and con-
trols, children had to be born on or
after 13 August 1998 and therefore eli-
gible to receive at least one dose of Hib
vaccine, either during the national
campaign or as part of the routine im-
munization series.
Control children were identified by
door-to-door visits in the neighbor-
hood where a case patient lived at the
time of the study. Briefly, trained in-
terviewers randomly chose a starting
direction from the case patient’s
house; at the fourth house, they asked
whether there was a child born within
a specified interval of the case pa-
tient’s birth date and continued inquir-
ing at every subsequent house until
three eligible control children were
identified. Control children with a his-
tory of meningitis were excluded.
Control children had to have been at
least 60 days old at the time of the case
patient’s illness, and they had to have
been residing in the National District
for at least 1 month before the case pa-
tient’s hospitalization. We used the
following criteria to match by age:
birth dates of matched controls had to
be within 60 days of the case patient’s
birth date if illness occurred within the
first year of life or within 180 days if
illness occurred between ages 1 and 4
years. Only one child in a household
was included.
For each case and control child,
trained interviewers administered a
questionnaire to the caregiver about
individual and household characteris-
tics (e.g., breastfeeding history, day-
care attendance, previous hospitaliza-
tions, parental education, household
crowding, housing conditions) and
vaccination history. Dates of vaccina-
tion were recorded from the child’s
health card, certificates from vaccina-
tion campaigns, or vaccination and
medical records at the health centers
where vaccinations were received. In
the absence of a documented vaccina-
tion history, interviewers solicited in-
formation about the route and site of
administration for each vaccination re-
ported by the caregiver. For case pa-
tients, vaccination history solicited at
the time of hospital admission was
used in the absence of other docu-
ments indicating vaccination status.
For the primary analysis estimating
the effectiveness of two or more doses
of Hib conjugate vaccine compared
with no vaccine, we assumed 90% ef-
fectiveness for two or more doses,
with 50% to 60% coverage for controls
receiving two or more doses of Hib
vaccine. With these parameters, the
sample size required 12–16 cases and
36–48 controls, with sufficient preci-
sion to exclude a lower confidence
bound of < 30%, approximately equal
to a power of 80%. For the secondary
analysis calculating the effectiveness
of one or more doses of Hib conjugate
vaccine compared with no vaccine, we
assumed 70% effectiveness for one or
more doses of Hib vaccine and esti-
mated that 70% of controls had re-
ceived at least one dose of Hib vaccine.
For the secondary analysis, the sample
size required 33 cases and 99 controls.
Analysis
We calculated cumulative incidence
rates by dividing the number of cases
hospitalized each calendar year
among children ages 2 to 59 months
resident in the National District by the
under-5 population of the district for
2002, estimated by a census conducted
that year. We calculated relative risk
(RR) and 95% confidence intervals
(CIs) comparing average rates of con-
firmed and probable bacterial menin-
gitis in 1998 and 1999, during active
surveillance, or in 2000 and 2001, dur-
ing passive surveillance, with rates 
for 2002 through 2004, after the intro-
duction of Hib conjugate vaccine. As
changes in surveillance may have con-
tributed to fewer cases of bacterial
meningitis identified after 1999, we
compared the odds of identifying Hib
as a cause of probable bacterial menin-
gitis (number of CSF specimens posi-
tive for Hib/number of specimens
negative for Hib) in 2000–2001 and
2002–2004 with the prevaccine period,
according to the method of Cowgill et
al. (16). To examine short-term effects
of the national Hib vaccination cam-
paign on disease incidence, we also
compared rates of Hib meningitis in
the National District during the 4
months after the campaign with rates
during the same 4 months in the pre-
ceding 3 years (1998–2000).  
For the case-control study, we calcu-
lated matched odds ratios (ORs) for
dichotomous variables and used
Wilcoxon’s rank sum test for continu-
ous variables. To compare vaccination
status, we calculated ORs and exact
95% CIs by using conditional logistic
regression. Vaccine effectiveness was
estimated as (1 – OR) × 100% (17). Un-
vaccinated children were the reference
group. Receipt of two or three doses of
Hib conjugate vaccine was combined
in the final analysis. Because vaccina-
tion status could not be determined for
several control children, we conducted
a sensitivity analysis assuming that all
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control children with unknown vacci-
nation status were not vaccinated.
Analyses were conducted in EpiInfo
version 6.04 (Centers for Disease Con-
trol and Prevention, Atlanta, Georgia)




From 1998 through 2004, there were
622 cases of meningitis among chil-
dren younger than 5 years of age who
met criteria for probable bacterial
meningitis. In all, there were 336 con-
firmed cases of bacterial meningitis
during the period; 21 (6%) confirmed
cases did not fulfill laboratory criteria
for probable bacterial meningitis. Hib
accounted for 172 of 336 (51%) con-
firmed cases (Table 1); 163 (95%) were
confirmed by culture and 113 (66%)
were positive by latex agglutination in
CSF. In 1998 and 1999, before wide-
spread use of conjugate vaccine, Hib
was the leading cause of bacterial
meningitis in children, accounting for
62% of confirmed cases and 31% of
probable cases. From 2002 through
2004, Hib accounted for 26% of con-
firmed cases and 13% of probable cases
of bacterial meningitis in children.
There were 44 fatal cases of probable
bacterial meningitis during the surveil-
lance period; of the 8 (18%) fatal cases
due to Hib, 1 occurred after the intro-
duction of Hib conjugate vaccine.
Between 1998 and 2004, the annual
cumulative incidence of probable bac-
terial meningitis decreased from 49 to
16 cases per 100 000 children in the Na-
tional District (Figure 1), a reduction of
33 cases per 100 000. Compared with
the average incidence in 1998 and
1999, rates of probable bacterial
meningitis in 2002 through 2004, after
the introduction of Hib conjugate vac-
cine, were 65% lower (RR, 0.35; 95%
CI, 0.25 to 0.48). Incidence of con-
firmed Hib meningitis decreased 84%
from 15 to 2 cases per 100 000 (rate dif-
ference, 13 cases per 100 000; RR, 0.16;
95% CI, 0.07 to 0.34). In addition, rates
of probable bacterial meningitis with
no determined etiology decreased
67%, from 25 to 8 cases per 100 000
(rate difference, 17 cases per 100 000;
RR, 0.33; 95% CI, 0.21 to 0.52). For 2002
through 2004, the incidence of con-
firmed Streptococcus pneumoniae men-
ingitis was not significantly different
from the prevaccine average (RR, 0.72;
95% CI, 0.35 to 1.47).
The number of cases of probable
bacterial meningitis and confirmed
Hib and S. pneumoniae meningitis were
lower in 2000 than in 1998 and 1999.
However, the odds of identifying Hib
from cases of probable bacterial men-
ingitis did not change during 2000–
2001 compared with the baseline 1998–
1999, suggesting that this decline was
not due to Hib vaccination (Table 2).
For the period 2002–2004, the odds of
identifying Hib from cases of probable
bacterial meningitis were significantly
lower than during the prevaccine pe-
riod. When we compared the inci-
dence of Hib meningitis during the 
4 months after the national Hib vacci-
nation campaign in 2001 with the same
4-month period in 1998–2000, we ob-
served no significant decline in inci-
dence of Hib meningitis (data not
shown).
Case-control study
We enrolled 32 of 41 (78%) eligible
children who had been hospitalized
with Hib meningitis after the national
Hib vaccination campaign in 2001; the
remaining 9 children could not be lo-
cated. Ten (31%) of the case patients had
received Hib conjugate vaccine, includ-
ing one who had received two doses of
vaccine before illness (Table 3). No case
patient received three doses of Hib con-
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TABLE 1. Meningitis cases among children < 5 years of age meeting criteria for probable bacterial meningitis or confirmed bacterial menin-
gitis, Clínica Infantil Robert Reid Cabral, Dominican Republic, 1998–2004
Before routine Hiba vaccination Routine Hib vaccination
Active surveillance Passive surveillance Passive surveillance
1998 1999 2000 2001 2002 2003 2004
Variable No. % No. % No. % No. % No. % No. % No. %
Probable bacterial meningitisb 149 100 145 100 97 100 80 100 68 100 36 100 47 100
Confirmed etiologyc 66 44 78 54 40 41 54 68 38 56 16 44 23 49
Unknown etiologyd 83 56 67 46 57 59 26 33 30 44 20 56 24 51
Confirmed bacterial meningitise 70 100 84 100 43 100 61 100 39 100 16 100 23 100
Haemophilus influenzae type b 45 64 50 60 31 72 26 43 12 31 2 13 6 26
Streptococcus pneumoniae 14 20 24 29 9 21 16 26 19 49 9 56 12 52
Neisseria meningitidis 6 4 3 2 2 2 4 5 2 3 0 0 4 9
Other 5 7 7 8 1 2 15 25 6 15 5 31 1 4
a Hib: Haemophilus influenzae type b.
b Defined as clinically diagnosed meningitis with either turbid cerebrospinal fluid (CSF) or two or more of the following: glucose < 40 mg/dL, protein > 45 mg/dL, ≥ 100 leukocytes/mm3, > 80%
polymorphonuclear cells.
c Defined as clinically diagnosed meningitis with either isolation of bacterial agent from CSF or positive latex agglutination test for bacterial antigen in CSF.
d Unknown etiology includes 180 cases with negative culture and latex agglutination results; 84 cases negative by culture, not tested for latex agglutination; 36 cases for which neither culture
nor latex agglutination was performed; and 6 cases for which results were not known. 
e Includes nine cases of meningitis due to Hib, three due to S. pneumoniae, two due to N. meningitidis, and seven due to other organisms that did not meet laboratory criteria for probable bac-
terial meningitis; seven Hib cases, three S. pneumoniae cases, and one N. meningitidis case were positive by latex agglutination only.
jugate vaccine before illness. From the
neighborhoods where case patients
resided at the time of illness, we identi-
fied 96 age-matched controls. Among
87 control children for whom any report
of vaccination history could be ob-
tained, 50 (57%) had received at least
one dose and 23 (26%) had received at
least two doses of Hib conjugate vaccine
before the case patient’s illness (Table
3). Control children were similar to case
patients with respect to sex, history of
breastfeeding, daycare attendance, ex-
posure to household smoke, parental
education, and possession of certain
household items (data not shown). At
the time of the study, households of
control children had fewer inhabitants
(median, 5 people; range, 2–11) than
households of case patients (median, 6
people; range, 3–11; P < 0.05).  
Using documented and verbal re-
ports of vaccination history, receipt of at
least two doses of Hib conjugate vaccine
was 94% effective (95% CI, 60% to
100%) against confirmed Hib meningi-
tis (Table 3). When analyses were lim-
ited to the 32 case patients and 71
matched control children with docu-
mented vaccination histories, two or
more doses were 92% effective (95% CI,
37% to 100%). In the sensitivity analysis,
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FIGURE 1.  Incidence of meningitis meeting criteria for probable bacterial etiology: Haemophilus influen-
zae type b (Hib) meningitis and Streptococcus pneumoniae meningitis among children < 5 years of age,
National District, Dominican Republic, 1998–2004
TABLE 2. Cases of probable bacterial meningitis among children < 5 years of age admitted
to Clínica Infantil Robert Reid Cabral, Dominican Republic, according to result of Haemo-
philus influenzae type b (Hib) laboratory tests and odds of positive Hib result 
Hib culture or latex result
Year Positive Negativea Odds of positive Hib result OR (95% CI)b
1998–1999 90 166 0.54 Referent
2000–2001 53 121 0.44 0.81 (0.52–1.24)
2002–2004 20 130 0.15 0.28 (0.16–0.50)c
a Excludes probable bacterial meningitis cases with no latex and no culture results.
b Odds ratios and exact 95% confidence intervals.
c P < 0.001.
TABLE 3. Doses of Haemophilus influenzae type b (Hib) vaccine received by children with
confirmed Hib meningitis and age-matched neighborhood control children, with estimates
of vaccine effectiveness 
Number of Hib No. of No. of
vaccine doses cases (%) controls (%) % effectiveness
receiveda n = 32 n = 87 OR (95% CI)b (95% CI)b
0 22 (69) 37 (43) Referent NAc
1 9 (28) 27 (31) 0.48 (0.12, 1.63) 52 (–63 to 88)
2 1 (3) 13 (15) 0.13 (0, 0.86) 87 (14 to 100)
3 0 10 (11) 0.10 (0, 0.67) 90 (33 to 100)
2 or 3d 1 (3) 23 (26) 0.06 (0, 0.40) 94 (60 to 100)
a Excludes 9 control children with unknown vaccination history. Sources of vaccine history included child health record or hos-
pital chart, supplementary vaccine cards distributed during immunization campaigns, and logbooks at vaccination posts; in-
cludes vaccine doses reported by parents of 3 case patients and 16 control children with no documented record.
b Odds ratios and exact 95% confidence intervals were calculated using conditional logistic regression. Vaccine effectiveness
is defined as 1 – OR.
c NA, not applicable.
d Includes all children who reported receiving two or three doses.
assuming all nine control children with
unknown vaccine history had not re-
ceived Hib vaccine, two or more doses
were 93% effective (95% CI, 55% to
100%). Including potential confounding
variables in bivariate models did not
change the effectiveness estimates for
receipt of at least two doses of Hib con-
jugate vaccine (data not shown).
DISCUSSION
Introduction of Hib conjugate vac-
cine into routine childhood immuni-
zations significantly reduced the inci-
dence of Hib meningitis among
children in the National District in the
Dominican Republic. In addition, Hib
vaccination was most likely responsi-
ble for significant reductions observed
in the incidence of probable bacterial
meningitis of undetermined etiology,
while the incidence of pneumococ-
cal meningitis did not change. Our
analyses suggest that the vaccine-
preventable burden of Hib disease was
greater than had been estimated previ-
ously (11), as has been demonstrated
in randomized trials of Hib conjugate
vaccines in developing countries (18).
Receipt of at least two doses of Hib
vaccine was highly effective in prevent-
ing meningitis among young children,
but the effectiveness of one dose was
not significant. The study was not able
to determine the effectiveness of the na-
tional campaign to administer a single
dose of Hib vaccine to all children < 3
years old before Hib conjugate was
added to the routine childhood series.
The estimated effectiveness of the Hib
component of the pentavalent combi-
nation vaccine in the routine immu-
nization program was similar to that of
Hib–tetanus toxoid conjugate vaccine
in Chile (19), Uganda (20), and The
Gambia (21) as well as to that of other
Hib conjugate vaccines (22).
Among the children enrolled as con-
trols in the case-control study, vaccine
coverage was lower than Ministry of
Health estimates. Lower coverage may
be due in part to vaccine availability,
as pentavalent vaccine was not avail-
able in all health posts throughout 
the National District until mid-2002.
Among control children born after
June 2002, 15 (68%) of 22 had received
one or more doses of Hib-containing
vaccine, approximately equivalent to
national estimates of Hib vaccine cov-
erage. The case-control investigation
suggested that undervaccination of el-
igible children contributed to ongoing
Hib disease transmission after intro-
duction of the vaccine.
This study demonstrates the value
of prevaccine surveillance for menin-
gitis that includes surrogate indicators
of bacterial meningitis using standard
laboratory definitions (7, 8). Reduc-
tions in rates of probable bacterial
meningitis of unknown etiology were
comparable to declines in confirmed
Hib meningitis, suggesting that the
vaccine-preventable burden of Hib
disease was higher than that con-
firmed by culture and antigen detec-
tion alone. Interestingly, no reduction
in culture-negative purulent meningi-
tis cases was noted after the introduc-
tion of Hib vaccine in Malawi, where
nearly 80% of cases of purulent menin-
gitis were confirmed by culture (23). In
the Dominican Republic, a substantial
proportion of Hib meningitis cases
may have been missed because of an-
tibiotic use before admission, insensi-
tivity of diagnostic methods, or speci-
mens that could not be tested.
In addition to acute morbidity and
mortality, Hib meningitis is associated
with neurologic sequelae such as hear-
ing loss and cognitive delay (24). This
retrospective review of hospital and
laboratory records was unable to eval-
uate the impact of Hib vaccination on
the proportion of Hib meningitis sur-
vivors who had neurologic sequelae
before and after introduction of the
vaccine.  Among etiologies of bacterial
meningitis, Hib was responsible for
most cases among children who re-
ceived auditory testing at CIRRC be-
tween 1993 and 2001, with more than
50% of those tested having docu-
mented hearing loss.5 Reduction in
long-term disability is an important
benefit of Hib vaccine introduction and
should be included in cost-effective-
ness analyses. The current evaluation
focused on meningitis, a small propor-
tion of the burden of Hib disease in de-
veloping countries. Pneumonia, which
makes up a larger proportion of the
global Hib disease burden, was not in-
cluded in the prevaccine surveillance
system, and the case-control study fo-
cused only on confirmed cases of Hib
meningitis. In two case-control studies
conducted in Latin America, Hib vac-
cination was 30% to 50% effective
against severe, x-ray-confirmed pneu-
monia among young children (25, 26).
This study has several limitations.
First, use of the Hib conjugate vaccine
before national immunization was not
well documented. In 1997, a donation
of Hib vaccine was used in a limited
campaign to administer a single dose
of vaccine to children 12 to 23 months
of age; reported coverage was 56% of
the target population (Expanded Pro-
gram on Immunization, Dominican
Republic, unpublished data). In addi-
tion, some children in the National Dis-
trict may have received Hib vaccine in
the private sector before it was intro-
duced nationwide. A second limitation
is the use of only one hospital for our
longitudinal study of meningitis sur-
veillance data and for case identifica-
tion for the case-control study. Meth-
ods of case identification and record
keeping were not maintained consis-
tently at other hospitals within the Na-
tional District after the active surveil-
lance period in 1998–1999. At CIRRC,
the largest number of cases of probable
bacterial meningitis was observed dur-
ing the active surveillance period, and
changes in record-keeping practices
after this period may account for ap-
parent declines in cases of bacterial
meningitis in 2000, before widespread
use of the Hib vaccine. Although
CIRRC is the major pediatric referral
hospital in the Dominican Republic,
the findings from our analysis of sur-
veillance data and the case-control
study may not be representative of the
population at large. Finally, the case-
control study of vaccine effectiveness
had limited power to consider poten-
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5 Feris JM, Fernández J, Terrera C, Peña C, Sánchez
J, Polanco D, et al. Factors associated with hearing
loss in Dominican children with bacterial meningi-
tis [poster presentation]. At: 3rd World Congress
of Pediatric Infectious Diseases, Santiago de Chile,
19–23 November 2002.
tial confounding factors, including the
presence of underlying illness among
cases. Estimates of vaccine effective-
ness remained high if we assumed that
control children with unknown vac-
cine histories were not vaccinated.
Countries in Latin America were
among the first developing countries
to introduce Hib conjugate vaccines in
routine immunization programs (4, 6),
beginning with Uruguay in 1994.  De-
spite early documented success, these
vaccines had not been introduced in
the poorer countries in the region be-
fore 2000 because of the high cost of
the vaccines. In 2006, the government
of the Dominican Republic began
purchasing pentavalent vaccine con-
taining Hib conjugate through the Pan
American Health Organization’s Re-
volving Fund, which purchases vac-
cines in bulk for countries in the re-
gion to obtain lower prices. This
decision required authorization from
the National Senate to increase the
budget allocation from 30 to 268 mil-
lion pesos per year (approximately
U.S. $8 million), an increase of 88%
(Expanded Program on Immuniza-
tion, Dominican Republic, unpub-
lished data). Demonstration of re-
duced disease burden after the
introduction of Hib conjugate vaccine
was important to justify the increase
in spending on immunization. When
governments are faced with the deci-
sion to increase immunization bud-
gets to sustain vaccination programs,
demonstration of vaccine impact and
effectiveness is critical to the decision-
making process.
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Objetivos. El uso generalizado de la vacuna contra Haemophilus influenzae tipo b
(Hib) ha permitido reducir radicalmente la carga de enfermedad por Hib en las Amé-
ricas. Pocos estudios han evaluado el impacto de la vacunación contra Hib sobre los
casos no confirmados mediante cultivo. En este estudio se analizaron las tendencias
en el número de casos probables de meningitis bacteriana antes y después de la in-
troducción de la vacuna contra Hib en la República Dominicana y se estimó la efica-
cia de la vacuna contra la meningitis.
Métodos. Se identificaron los casos de meningitis en niños menores de 5 años a par-
tir de los registros de ingreso del principal hospital pediátrico de Santo Domingo
entre 1998 y 2004. Los casos de meningitis con probable etiología bacteriana se clasi-
ficaron según criterios de laboratorio; los casos confirmados contaban con cultivo bac-
teriano positivo o detección de antígenos específicos en el líquido cefalorraquídeo. Se
calcularon las tasas de incidencia acumulada de casos confirmados y probables de
meningitis en los niños que vivían en el Distrito Nacional. Los casos confirmados de
meningitis por Hib se incorporaron a un estudio de casos y controles —pareados
según la edad y el barrio de residencia— para calcular la eficacia de la vacuna.
Resultados. Antes de la introducción de la vacuna, la tasa anual de meningitis de
posible etiología bacteriana era de 49 casos por 100 000 niños menores de 5 años; de
los casos confirmados de origen bacteriano, 60% fue por Hib. En el período 2002–2004,
después de la introducción de la vacuna, la tasa anual de meningitis de posible etio-
logía bacteriana fue de 16 casos por 100 000, es decir 65% más baja, y 26% de los casos
confirmados correspondieron a Hib. Las tasas de meningitis por Hib y de posible
origen bacteriano de etiología desconocida se redujeron en 13 y 17 casos por 100 000,
respectivamente.
Conclusiones. La introducción de la vacuna contra Hib redujo sustancialmente la in-
cidencia de casos de meningitis confirmados y probables en la República Dominicana.
El impacto estimado de la vacunación contra Hib fue dos veces mayor cuando se con-
sideraron los casos no confirmados mediante cultivo.
Haemophilus influenzae type b, vacunas contra Haemophilus, meningitis bacteriana,
inmunización, República Dominicana.
RESUMEN
Impacto de la vacuna
conjugada contra
Haemophilus influenzae tipo b
sobre la meningitis bacteriana
en la República Dominicana
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